Collaboration and innovation: Advancing technology solutions to reduce maternal mortality
Methods: Merck, through its 10-year $500-million Merck for Mothers initiative, and PATH applied their expertise, a novel health impact model created by Research Triangle Institute, and a PATH-developed assessment tool involving two dozen criteria to evaluate 38 innovations to prevent, diagnose and treat the leading causes of maternal death—post-partum hemorrhage and pre-eclampsia/eclampsia.
Major results: For the first time, the global health community has an in-depth, comparative assessment that can guide investment in innovations to reduce maternal mortality— an invaluable resource when funds are scarce.
Recommendations: The global health community can use the assessment process and findings to (1) build a roadmap to advance technologies with the greatest potential to save lives, (2) pinpoint ways to improve existing products, (3) support informed decisions about where to invest to have the greatest impact on reducing maternal mortality and (4) catalyze and coordinate multi-sector action to advance high-potential technologies.
Implementation of health education strategies, interventions and programs
Provision of health care to the public
Public health or related research
List three major hurdles preventing women from accessing life-saving technologies in resource-poor settings Explain a process to develop a comparative assessment of health technologies
Keywords: Technology, Maternal Health
Qualified on the content I am responsible for because: Bill Martin is an established public health professional. He led the Secretariat for the Every Woman Every Child Initiative, has experience coordinating with WHO and other leaders in the health care industry, and has extensive experience developing and marketing health technologies.
Any relevant financial relationships? Yes
|Name of Organization||Clinical/Research Area||Type of relationship|
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.